BioCentury
ARTICLE | Clinical News

BerGenBio gains on Phase II data for AXL inhibitor

January 29, 2018 9:35 PM UTC

BerGenBio ASA (OSE:BGBIO) gained NOK5.80 (16%) to NOK41 on Monday after it reported data from its Phase II trials of bemcentinib (BGB324) to treat acute myelogenous leukemia (AML) and other cancers. Data were presented at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco.

Among 35 evaluable patients with relapsed or refractory AML or myelodysplastic syndrome (MDS) in the Phase II portion of the Phase Ib/II BGBC003 trial, bemcentinib as monotherapy led to two complete responses with incomplete recovery of peripheral counts (CRi) and five partial responses, plus eight cases of stable disease for more than four months. BGBC003 is enrolling up to 75 patients and is also evaluating bemcentinib plus cytarabine and decitabine...